Cross-clade immune responses after immunization with a whole-killed gp120-depleted human immunodeficiency virus type-1 immunogen in Incomplete Freund's adjuvant (HIV-1 immunogen, REMUNE™) in human immunodeficiency virus type-1 seropositive subjects

被引:25
作者
Moss, RB
Giermakowska, W
Lanza, P
Turner, JL
Wallace, MR
Jensen, FC
Theofan, G
Richieri, SP
Carlo, DJ
机构
[1] Immune Response Corp, Carlsbad, CA 92008 USA
[2] Univ Penn, Grad Hosp, Philadelphia, PA 19104 USA
[3] USN, Med Ctr, San Diego, CA 92152 USA
关键词
D O I
10.1089/vim.1997.10.221
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Lymphocyte proliferation responses to gp120-depleted HZ321 virus (clade A) antigen were compared to BAL human immunodeficiency virus (HIV) virus antigen (clade B) responses, clade E HIV virus antigen responses, and purified native p24 antigen responses in 15 human immunodeficiency virus type-1 (HIV-1) seropositive subjects immunized with a whole-killed inactivated gp120-depleted HIV-1 antigen in Incomplete Freund's adjuvant (HIV-1 immunogen, REMUNE(TM)). A significant increase in lymphocyte proliferation to HZ321 antigen was observed after immunization with the HIV-1 immunogen (p = 0.02). A strong association was demonstrated between the HIV-I immunizing antigen, HZ321, and native p24 antigen responses (r = 0.80, p < 0.0001). Furthermore, a strong association in terms of proliferative responses was demonstrated between HZ321 virus (clade A) responses and BAL virus (clade B) (r = 0.95, p < 0.0001) and clade E virus antigen (r = 0.92, g < 0.0001). Proliferative responses to HIV antigens also correlated with baseline CD4 counts. Taken together, these results support the specificity of immune responses induced by REMUNE (HIV-1 immunogen). The development of cross-reactive immune responses between clades and to the more conserved epitopes of the virus have implications in the development of therapeutic and prophylactic HIV vaccines.
引用
收藏
页码:221 / 228
页数:8
相关论文
共 19 条
[1]   Relation of impaired lymphocyte proliferative function to other major human immunodeficiency virus type 1-induced immunological changes [J].
Bass, HZ ;
Fahey, JL ;
Nishanian, P ;
Detels, R ;
Cumberland, W ;
Kemeny, M ;
Plaeger, S .
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 1997, 4 (01) :64-69
[2]   Differential regulation of the antibody responses to Gag and Env proteins of human immunodeficiency virus type 1 [J].
Binley, JM ;
Klasse, PJ ;
Cao, YZ ;
Jones, I ;
Markowitz, M ;
Ho, DD ;
Moore, JP .
JOURNAL OF VIROLOGY, 1997, 71 (04) :2799-2809
[3]   HIV type 1 isolate Z321, the strain used to make a therapeutic HIV type 1 immunogen, is intersubtype recombinant [J].
Choi, DJ ;
Dube, S ;
Spicer, TP ;
Slade, HB ;
Jensen, FC ;
Poiesz, BJ .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 1997, 13 (04) :357-361
[4]   Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers [J].
Ferrari, G ;
Humphrey, W ;
McElrath, MJ ;
Excler, JL ;
Duliege, AM ;
Clements, ML ;
Corey, LC ;
Bolognesi, DP ;
Weinhold, KJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (04) :1396-1401
[5]   GENETIC-VARIATION OF HIV TYPE-1 IN 4 WORLD-HEALTH-ORGANIZATION-SPONSORED VACCINE EVALUATION SITES - GENERATION OF FUNCTIONAL ENVELOPE (GLYCOPROTEIN-160) CLONES REPRESENTATIVE OF SEQUENCE SUBTYPE-A, SUBTYPE-B, SUBTYPE-C, AND SUBTYPE-E [J].
GAO, F ;
YUE, L ;
CRAIG, S ;
THORNTON, CL ;
ROBERTSON, DL ;
MCCUTCHAN, FE ;
BRADAC, JA ;
SHARP, PM ;
HAHN, BH ;
OSMANOV, S ;
BELSEY, EM ;
HEYWARD, W ;
ESPARZA, J ;
GALVAOCASTRO, B ;
VANDEPERRE, P ;
KARITA, E ;
WASI, C ;
SEMPALA, S ;
TUGUME, B ;
BIRYAHWAHO, B ;
RUBSAMENWAIGMANN, H ;
VONBRIESEN, H ;
ESSER, R ;
GREZ, M ;
HOLMES, H ;
NEWBERRY, A ;
RANJBAR, S ;
TOMLINSON, P ;
BRADAC, J ;
MCCUTCHAN, F ;
LOUWAGIE, J ;
HEGERICH, P ;
LOPEZGALINDEZ, C ;
OLIVARES, I ;
DOPAZO, J ;
MULLINS, JI ;
DELWART, EL ;
BACHMANN, HM ;
GOUDSMIT, J ;
DEWOLF, F ;
SARAGOSTI, S ;
SCHOCHETMAN, G ;
KALISH, M ;
LUO, CC ;
GEORGE, R ;
PAU, CP ;
WEBER, J ;
CHEINGSONGPOPOV, R ;
KALEEBU, P ;
NARA, P .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 1994, 10 (11) :1359-1368
[6]   HUMAN-IMMUNODEFICIENCY-VIRUS ISOLATED FROM A SERUM SAMPLE COLLECTED IN 1976 IN CENTRAL-AFRICA [J].
GETCHELL, JP ;
HICKS, DR ;
SVINIVASAN, A ;
HEATH, JL ;
YORK, DA ;
MALONGA, M ;
FORTHAL, DN ;
MANN, JM ;
MCCORMICK, JB .
JOURNAL OF INFECTIOUS DISEASES, 1987, 156 (05) :833-837
[7]   EFFECT OF GAMMA-IRRADIATION ON THE HUMAN IMMUNODEFICIENCY VIRUS AND HUMAN COAGULATION PROTEINS [J].
KITCHEN, AD ;
MANN, GF ;
HARRISON, JF ;
ZUCKERMAN, AJ .
VOX SANGUINIS, 1989, 56 (04) :223-229
[8]  
LANZA P, 1998, IN PRESS VACCINE
[9]  
LEDERMAN M, 1997, PARTIAL IMMUNE RECON
[10]   INVESTIGATIONS OF THE USE OF BETA-PROPIOLACTONE IN VIRUS INACTIVATION [J].
LOGRIPPO, GA .
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1960, 83 (04) :578-594